Curis (CRIS) to Release Earnings on Thursday

Curis (NASDAQ:CRIS) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect Curis to post earnings of ($1.70) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.11). Curis had a negative net margin of 486.45% and a negative return on equity of 224.75%. The business had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $2.31 million. During the same quarter in the previous year, the company earned ($2.40) earnings per share. On average, analysts expect Curis to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Curis Stock Performance

NASDAQ CRIS opened at $5.81 on Wednesday. The company has a 50-day simple moving average of $7.93 and a two-hundred day simple moving average of $10.67. Curis has a 12-month low of $3.80 and a 12-month high of $17.49.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CRIS shares. Truist Financial reiterated a “buy” rating and set a $26.00 target price on shares of Curis in a report on Wednesday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Curis in a report on Wednesday, May 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of Curis in a report on Wednesday, May 15th.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.